课题基金 / 基金详情

Direct Oral Anticoagulants, Warfarin, and the Risk of Adverse Renal Outcomes Among People with Non-Valvular Atrial Fibrillation

Direct Oral Anticoagulants, Warfarin, and the Risk of Adverse Renal Outcomes Among People with Non-Valvular Atrial Fibrillation
直接口服抗凝剂、华法林与非瓣膜性心房颤动患者肾脏不良后果的风险
批准号：
454493
负责人：
salmasi shahrzad
金额：
$9.83万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-10-01 至 2024-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=454493&lang=en
关键词：
Acute Kidney Injury Atrial Fibrillation Drug Safety And Effectiveness Oral Anticoagulants Prevalent New User Design

项目摘要

项目成果

salmasi shahrzad的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
People with atrial fibrillation (or AF, a type of abnormal heartbeat) have a much higher risk of having a stroke than people without AF. Blood thinning drugs (called anticoagulants), such as direct oral anticoagulants (or DOACs) and warfarin, have been sh
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Quantitative exploration of AF patients' knowledge gaps: a systematic review and meta-analysis
  • 批准号：
    391548
  • 项目类别：
  • 资助金额：
    $0.05万
  • 财政年份：
    2018
  • 负责人：
    salmasi shahrzad
  • 依托单位：
    University of British Columbia
海外基金